The Behavioral/Dysexecutive Variant of Alzheimer's Disease: A Case Series with Clinical, Neuropsychological, and FDG-PET Characterization.


Journal

Dementia and geriatric cognitive disorders
ISSN: 1421-9824
Titre abrégé: Dement Geriatr Cogn Disord
Pays: Switzerland
ID NLM: 9705200

Informations de publication

Date de publication:
2020
Historique:
received: 12 05 2020
accepted: 27 08 2020
pubmed: 19 11 2020
medline: 16 6 2021
entrez: 18 11 2020
Statut: ppublish

Résumé

It is well known that some patients with Alz-heimer's disease (AD) have atypical, nonamnestic presentations. While logopenic aphasia and posterior cortical atrophy are well-characterized atypical variants of AD, the behavioral/dysexecutive variant remains a controversial entity, lacking consensus regarding its distinctive clinical and imaging features. We present a case series of 8 patients with biomarker confirmation of AD (cerebrospinal fluid [CSF] analysis or amyloid positron emission tomography [PET]) and a progressive frontal syndrome, defined as prominent behavioral and/or executive deficits at initial presentation. We characterize the cohort based on clinical features, cognitive performance in 4 domains (memory, visuospatial, executive, and language) as well as behavior on the Dépistage Cognitif de Québec (DCQ), and regional brain metabolism using 18F-fluorodeoxyglucose PET (FDG-PET). We compare these features with 8 age-matched patients diagnosed with the behavioral variant of frontotemporal dementia (bvFTD) and 37 patients with typical amnestic AD. Patients with the behavioral/dysexecutive variant of AD presented with early-onset (mean age: 59 years old) progressive executive and behavioral problems reminiscent of bvFTD, including disinhibition, loss of social conventions, and hyperorality. Patients scored higher on the Memory Index and lower on the Behavioral Index than patients with amnestic AD on the DCQ, yet they were indistinguishable from patients with bvFTD on each of the cognitive indices. Visual analysis of FDG-PET revealed half of patients with behavioral/dysexecutive AD presented with frontal hypometabolism suggestive of bvFTD and only 3/8 (37.5%) presented significant hypometabolism of the posterior cingulate cortex. Group-level analysis of FDG-PET data revealed that the most hypometabolic regions were the middle temporal, inferior temporal, and angular gyri in behavioral/dysexecutive AD and the inferior frontal gyrus, anterior cingulate cortex, caudate nucleus, and insula in bvFTD. The behavioral/dysexecutive variant of AD is a rare, atypical young-onset variant of AD defined clinically by early and prominent impairments in executive and behavioral domains. While behavioral/dysexecutive AD is hardly distinguishable from bvFTD using clinical and cognitive features alone, CSF biomarkers and temporoparietal hypometabolism help predict underlying pathology during life.

Identifiants

pubmed: 33207355
pii: 000511210
doi: 10.1159/000511210
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

518-525

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

David Bergeron (D)

Clinique Interdisciplinaire de Mémoire (CIME) du CHU de Québec, Université Laval, Québec, Québec, Canada, david.bergeron.5@ulaval.ca.

Leila Sellami (L)

Clinique Interdisciplinaire de Mémoire (CIME) du CHU de Québec, Université Laval, Québec, Québec, Canada.

Stéphane Poulin (S)

Clinique Interdisciplinaire de Mémoire (CIME) du CHU de Québec, Université Laval, Québec, Québec, Canada.

Louis Verret (L)

Clinique Interdisciplinaire de Mémoire (CIME) du CHU de Québec, Université Laval, Québec, Québec, Canada.

Rémi W Bouchard (RW)

Clinique Interdisciplinaire de Mémoire (CIME) du CHU de Québec, Université Laval, Québec, Québec, Canada.

Robert Laforce (R)

Clinique Interdisciplinaire de Mémoire (CIME) du CHU de Québec, Université Laval, Québec, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH